AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Reproductive system or breast disease

cervical cancer

A primary or metastatic malignant neoplasm involving the cervix.

🔔 Follow weekly
🧬13651genes / proteins with evidence
💊232drugs and clinical candidates
🧪12+recruiting trials worldwide
✅6approved
📈42phase 3
🧬

Understand cervical cancer

Cancer · Cells that grow out of control
🎓 Learn more

What it is

Cervical cancer is cancer that starts in the cells of the cervix. The cervix is part of the female reproductive system. It is the lower, narrow end of the uterus (womb), which opens into the vagina (birth canal).

Cervical cancer usually develops slowly. Before cervical cells become cancer, they start to look abnormal. These cells are called "precancers." If they aren't destroyed or removed, they may become cancer cells that grow out of control and spread to other parts of your body.

Screening tests for cervical cancer can help find abnormal cells so you can get treatment to prevent cervical cancer. These tests can also find cervical cancer early when it's usually easier to treat.

From MedlinePlus: Cervical Cancer (US National Library of Medicine) ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for cervical cancer itself.

🤖

AI briefing

Where the science on cervical cancer stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens cervical cancer.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
FGFR3 fibroblast growth factor receptor 3PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.72
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.66
TOP1 DNA topoisomerase IPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.62
FBXW7 F-box and WD repeat domain containing 7PROTACsmall molecule🧊 AlphaFold structure ↗ 0.62
VEGFA vascular endothelial growth factor APROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.62
STK11 serine/threonine kinase 11PROTACsmall molecule🧊 AlphaFold structure ↗ 0.61
EP300 EP300 lysine acetyltransferasePROTACsmall molecule🧊 AlphaFold structure ↗ 0.60
KMT2D lysine methyltransferase 2DPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.60
TUBB3 tubulin beta 3 class IIIPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBA1A tubulin alpha 1aPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBA1C tubulin alpha 1cPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
KMT2C lysine methyltransferase 2CPROTACsmall molecule🧊 AlphaFold structure ↗ 0.59
TUBA1B tubulin alpha 1bPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBB tubulin beta class IPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBA4A tubulin alpha 4aPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.59

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to cervical cancer, by how far it has got
Approved · 6
AbobotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitorApproved
BevacizumabVascular endothelial growth factor A inhibitorApproved
CemiplimabProgrammed cell death protein 1 inhibitorApproved
IncobotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitorApproved
Tisotumab VedotinTubulin inhibitor; Coagulation factor III binding agentApproved
TopotecanDNA topoisomerase I inhibitorApproved
In phase 2 / 3 · 20
AdebrelimabProgrammed cell death 1 ligand 1 inhibitorPhase 3
BalstilimabProgrammed cell death protein 1 antagonistPhase 3
Bleomycin SulfatePhase 3
Bulumtatug FuvedotinPhase 3
CadonilimabProgrammed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitorPhase 3
CamrelizumabProgrammed cell death protein 1 antagonistPhase 3
Show all 20
CarboplatinPhase 3
CisplatinPhase 3
DocetaxelTubulin inhibitorPhase 3
DurvalumabProgrammed cell death 1 ligand 1 inhibitorPhase 3
EnlonstobartPhase 3
Epoetin AlfaErythropoietin receptor agonistPhase 3
FamitinibStem cell growth factor receptor inhibitor; Vascular endothelial growth factor receptor 1…Phase 3
FluorouracilThymidylate synthase inhibitorPhase 3
GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Phase 3
HydralazinePhase 3
IfosfamidePhase 3
IrinotecanDNA topoisomerase I inhibitorPhase 3
Magnesium ValproatePhase 3
MethotrexateDihydrofolate reductase inhibitorPhase 3
Early trials · 20
AdavosertibSerine/threonine-protein kinase WEE1 inhibitorPhase 1/2
AfuresertibSerine/threonine-protein kinase AKT inhibitorPhase 1/2
BirinapantcIAP1/cIAP2 inhibitorPhase 1/2
CelecoxibCyclooxygenase-2 inhibitorPhase 1/2
DaratumumabLymphocyte differentiation antigen CD38 inhibitorPhase 1/2
Denileukin DiftitoxElongation factor 2 inhibitor; Interleukin-2 receptor binding agentPhase 1/2
Show all 20
GimeracilDihydropyrimidine dehydrogenase inhibitorPhase 1/2
Ifinatamab DeruxtecanPhase 1/2
Immunocytokine Nhs-Il12Phase 1/2
IpatasertibSerine/threonine-protein kinase AKT inhibitorPhase 1/2
Lutetium Lu 177 Zadavotide GuraxetanPhase 1/2
Lutetium Lu-177 Vipivotide TetraxetanGlutamate carboxypeptidase II binding agentPhase 1/2
Lutetium Lu177 EdotreotidePhase 1/2
Lutetium Oxodotreotide Lu-177Somatostatin receptor binding agentPhase 1/2
MapatumumabTRAIL receptor-1 agonistPhase 1/2
MonalizumabNKG2-A/NKG2-B type II integral membrane protein inhibitorPhase 1/2
Neo-201Phase 1/2
Peltopepimut-SPhase 1/2
SorafenibSerine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor be…Phase 1/2
SubasumstatPhase 1/2
🧪

Recruiting trials

Worldwide, open to new patients now
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemot…NCT06019455 · n/a · 📍 GuangzhouAI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective StudyNCT07326358 · n/a · 📍 ShanghaiGenetic Determinants of Barrett's Esophagus and Esophageal AdenocarcinomaNCT00288119 · n/a · 📍 BaltimoreThe Ohio State University (OSU) SCREEN Community ProgramNCT06666192 · NA · 📍 ColumbusGETNE Registration of Thyroid CancerNCT03765333 · n/a · 📍 BarcelonaTirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCCNCT05941338 · Phase 2 · 📍 GuangzhouVMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or…NCT03556228 · Phase 1, Phase 2 · 📍 Santa RosaSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)NCT06780111 · Phase 1, Phase 2 · 📍 PittsburghClinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal CancerNCT07367516 · Phase 1, Phase 2 · 📍 HefeiA Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastr…NCT07692204 · Phase 2 · 📍 ShanghaiTumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell CarcinomaNCT06606028 · n/a · 📍 San FranciscoPostoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal CarcinomaNCT05937438 · Phase 1, Phase 2 · 📍 Hefei Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy